Literature DB >> 27848010

Reliability of the Arabic Glasgow benefit inventory after otolaryngology interventions.

Bshair Aldriweesh1, Mashael Alharbi1, Abdulrahman Alkhatib1, Ali Almomen1, Musaed Alzahrani2.   

Abstract

We aim to translate the Glasgow benefit inventory (GBI) questionnaire into Arabic language and assess its reliability in scoring the benefit of patients after otolaryngology interventions. This is a pilot study of an ongoing prospective cohort study. The original GBI questionnaire was translated into Arabic language and back-translated into English by two different experts. The questionnaire was given to patients who were asked to fill it themselves. A group of consecutive adult patients were included in the study. Fifty-one patients were included. Reliability using Cronbach's α was higher than 0.70 for total score and the three subscales. Five loading factors explained 72.9% of the variance reached. The mean benefit of the GBI total score was 30.0 ± 36.37. Subscales scores were as follows: 35.21 ± 25.98 for the general health, 25.81 ± 45.98 for the physical benefit and 29.08 ± 34.45 for the social support. The Arabic GBI questionnaire is reliable to evaluate the quality of life after otolaryngology interventions for Arabic speaking population.

Entities:  

Keywords:  Factor analysis and Saudi Arabia; Otolaryngology; Quality of life; Reliability

Mesh:

Year:  2016        PMID: 27848010     DOI: 10.1007/s00405-016-4373-y

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  9 in total

1.  What quality of life? The WHOQOL Group. World Health Organization Quality of Life Assessment.

Authors: 
Journal:  World Health Forum       Date:  1996

2.  The HEAR-QL: quality of life questionnaire for children with hearing loss.

Authors:  Amy M Umansky; Donna B Jeffe; Judith E C Lieu
Journal:  J Am Acad Audiol       Date:  2011 Nov-Dec       Impact factor: 1.664

3.  Reliability and validity of the Spanish Glasgow Benefit Inventory after cochlear implant surgery in adults.

Authors:  Isabel Sanchez-Cuadrado; Luis Lassaletta; Rosa Perez-Mora; Elena Muñoz; Javier Gavilan
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-12-13       Impact factor: 2.503

4.  Validation of a quality-of-life instrument for laryngopharyngeal reflux.

Authors:  Ricardo L Carrau; Aliaa Khidr; Karen F Gold; Joseph A Crawley; Eric M Hillson; Jamie A Koufman; Chris L Pashos
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2005-04

5.  Development of the Tinnitus Handicap Inventory.

Authors:  C W Newman; G P Jacobson; J B Spitzer
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1996-02

6.  Measuring patient benefit from otorhinolaryngological surgery and therapy.

Authors:  K Robinson; S Gatehouse; G G Browning
Journal:  Ann Otol Rhinol Laryngol       Date:  1996-06       Impact factor: 1.547

7.  Health-related quality of life before and after management in adults referred to otolaryngology: a prospective national study.

Authors:  I R C Swan; F H Guy; M A Akeroyd
Journal:  Clin Otolaryngol       Date:  2012-02       Impact factor: 2.597

8.  Psychometric evaluation of the SF-36 health survey in Medicare managed care.

Authors:  Barbara Gandek; Samuel J Sinclair; Mark Kosinski; John E Ware
Journal:  Health Care Financ Rev       Date:  2004

Review 9.  The Quality of Life Scale (QOLS): reliability, validity, and utilization.

Authors:  Carol S Burckhardt; Kathryn L Anderson
Journal:  Health Qual Life Outcomes       Date:  2003-10-23       Impact factor: 3.186

  9 in total
  2 in total

1.  Psychometric properties of the Swedish version of the Glasgow Benefit Inventory in otosclerosis subjects.

Authors:  Ylva Dahlin Redfors; Radoslava Jönsson; Bo Tideholm; Caterina Finizia
Journal:  Laryngoscope Investig Otolaryngol       Date:  2019-11-27

2.  Reliability of the Arabic Glasgow children's benefit inventory.

Authors:  Musaed A Alzahrani; Bshair A Aldriweesh; Mashael A Alharbi; Taghrid N Alrashidi
Journal:  Saudi Med J       Date:  2020-10       Impact factor: 1.484

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.